(ACAD) ACADIA Pharmaceuticals - Performance 33.2% in 12m
ACAD performance: live returns, drawdowns, peer ranking & SPY comparison from 1w to 5y, all in one clean chart-driven dashboard.
Performance Rating
-41.02%
#54 in Peer-Group
Rel. Strength
76.92%
#1715 in Stock-Universe
Total Return 12m
33.17%
#32 in Peer-Group
Total Return 5y
-60.22%
#69 in Peer-Group
| P/E | Value |
|---|---|
| P/E Trailing | 16.2 |
| P/E Forward | 45.3 |
| High / Low | USD |
|---|---|
| 52 Week High | 22.95 USD |
| 52 Week Low | 14.10 USD |
| Sentiment | Value |
|---|---|
| VRO Trend Strength +-100 | 39.94 |
| Buy/Sell Signal +-5 | -1.12 |
| Support / Resistance | Levels |
|---|---|
| Support | |
| Resistance |
12m Total Return: ACAD (33.2%) vs XBI (-10.7%)
5y Drawdown (Underwater) Chart
Top Performer in Biotechnology
Overall best picks of Peer Group - Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability | EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| GILD NASDAQ Gilead Sciences |
3.32% | 68% | 77.8% | 22.7 | 13.6 | 0.23 | 28.3% | -3.71% |
| UTHR NASDAQ United Therapeutics |
-10.6% | -8.81% | 144% | 11.3 | 10.5 | 1.43 | 74.6% | 16.1% |
| AMGN NASDAQ Amgen |
0.71% | -3.57% | 32.5% | 25.4 | 13.4 | 0.93 | 0.60% | 41% |
| BIM PA Biomerieux |
-0.36% | 31.7% | -6.18% | 33.1 | 25.8 | 1.55 | -38.5% | -25.1% |
| NBIX NASDAQ Neurocrine Biosciences |
2.76% | -8.64% | 0.27% | 43 | 24.8 | 0.27 | 18.7% | -34.3% |
| KMDA NASDAQ Kamada |
12.5% | 65.3% | -5.65% | 25.5 | 22.8 | 0.91 | 48.1% | 3.93% |
| PTCT NASDAQ PTC Therapeutics |
-0.49% | 55.9% | -10.1% | 7.71 | 6.26 | 0.81 | - | 68% |
| ERF PA Eurofins Scientific SE |
3.44% | 35.3% | 14.7% | 28.9 | 15.4 | 0.64 | -62.1% | -19.3% |
Performance Comparison: ACAD vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for ACAD
| Total Return (including Dividends) | ACAD | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -0.49% | 2.27% | 4.52% |
| 3 Months | 30.88% | 6.30% | 10.43% |
| 12 Months | 33.17% | -10.68% | 14.67% |
| 5 Years | -60.22% | -26.13% | 109.23% |
| Trend Score (consistency of price movement) | ACAD | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 26.1% | 5.5% | 79.1% |
| 3 Months | 82.4% | 74.3% | 94.2% |
| 12 Months | 35.3% | -84.7% | 44.4% |
| 5 Years | -50.5% | -52.6% | 84% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
|---|---|---|---|
| 1 Month | %th54.50 | -2.70% | -4.79% |
| 3 Month | %th77.50 | 23.12% | 18.52% |
| 12 Month | %th85.00 | 49.08% | 16.13% |
| 5 Years | %th67.00 | -46.14% | -80.99% |
FAQs
Does ACADIA Pharmaceuticals (ACAD) outperform the market?
Yes,
over the last 12 months ACAD made 33.17%, while its related Sector, the SPDR S&P Biotech (XBI) made -10.68%.
Over the last 3 months ACAD made 30.88%, while XBI made 6.30%.
Performance Comparison ACAD vs Indeces and Sectors
Above 0 means better perfomance compared to Symbol in this Timeframe
ACAD vs. Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -6.5% | -5% | 8.2% | 19% |
| US NASDAQ 100 | QQQ | -6% | -5.2% | 7% | 19% |
| German DAX 40 | DAX | -4.8% | 0.6% | -3.3% | 4% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -5.5% | -4.7% | 7.3% | 16% |
| Hongkong Hang Seng | HSI | -4.7% | -6.6% | -9.6% | -3% |
| India NIFTY 50 | INDA | -6.6% | -2.9% | 9.9% | 33% |
| Brasil Bovespa | EWZ | -7.6% | -8% | -14.7% | 20% |
ACAD vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -7.1% | -6.5% | 3.1% | 5% |
| Consumer Discretionary | XLY | -5.9% | -2.6% | 15.4% | 13% |
| Consumer Staples | XLP | -5.5% | -0.1% | 8.6% | 23% |
| Energy | XLE | -5.3% | -4.8% | 14.3% | 36% |
| Financial | XLF | -6.8% | -4.1% | 4.5% | 3% |
| Health Care | XLV | -6.9% | -4% | 14.3% | 37% |
| Industrial | XLI | -6.7% | -4.6% | 1.1% | 9% |
| Materials | XLB | -7.5% | -4.7% | 5.1% | 28% |
| Real Estate | XLRE | -3.4% | -1.2% | 9.4% | 20% |
| Technology | XLK | -6.2% | -8.4% | 5.9% | 22% |
| Utilities | XLU | -5.1% | -0.9% | 5.5% | 9% |
| Aerospace & Defense | XAR | -7.2% | -7.7% | -10.2% | -16% |
| Biotech | XBI | -3.8% | -2.8% | 23.7% | 44% |
| Homebuilder | XHB | -9.1% | -11% | 14.8% | 28% |
| Retail | XRT | -7.5% | -5% | 13.9% | 24% |
ACAD vs. Commodities
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Oil | USO | -6% | -6.79% | 18.4% | 43% |
| Natural Gas | UNG | 2.3% | 9.9% | 25.6% | 42% |
| Gold | GLD | -5.1% | 0.8% | -10.9% | -10% |
| Silver | SLV | -5.1% | -4.1% | -7.1% | 11% |
| Copper | CPER | -7.6% | -4.4% | -10.2% | 18% |
ACAD vs. Bonds
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| iShares 20+ Years Bond | TLT | -5.5% | -4% | 12% | 31% |
| iShares High Yield Corp. Bond | HYG | -4.7% | -1.7% | 10.3% | 23% |